P2.09. Clinical Characteristics and Outcomes of Patients with EGFR-mutant Lung Cancer with Acquired BRAF Alterations - PDF(Slides)
Back to course
Pdf Summary
Asset Subtitle
Jane Sui
Meta Tag
Speaker Jane Sui
Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2
Keywords
EGFR-mutant lung cancer
acquired BRAF alterations
EGFR tyrosine kinase inhibitors
clinical characteristics
patient outcomes
non-small cell lung cancer
osimertinib
erlotinib
RAF/MEK inhibitors
adverse events
Powered By